| Name | Sparfloxacin |
| Description | Sparfloxacin (CI-978) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, thus preventing DNA replication and transcription. |
| In vitro | Orally administered Sparfloxacin produces favorable therapeutic outcomes in mice with systemic infections caused by Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Escherichia coli, and Pseudomonas aeruginosa. |
| In vivo | Sparfloxacin targets DNA gyrase, inhibiting DNA synthesis. It exhibits potent, broad-spectrum antimicrobial activity, effective against Gram-positive bacteria such as Staphylococcus, Streptococcus, and Enterococcus species (MIC=0.1 to 0.78μg/ml), Gram-negative bacteria including Enterobacteriaceae and Pseudomonas species (MIC=0.0125 to 1.56μg/ml), glucose non-fermenters (MIC=0.025 to 0.78μg/ml), Legionella (MIC=0.0125 to 0.05μg/ml), and anaerobes (MIC=0.2 to 0.78μg/ml). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1 mg/ml, Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | CI978 | AT 4140 | AT4140 | Inhibitor | inhibit | Sparfloxacin | Antibiotic | PD131501 | Bacterial | PD-131501 | CI 978 |
| Inhibitors Related | Neomycin sulfate | Dimethyl sulfoxide |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
United States
